MDC’s burden of illness study
La française suit
If you have a neuromuscular disorder or care for someone who does, we need your help! You are invited to participate in a questionnaire on the costs of living with a neuromuscular disorder and the impact of neuromuscular disorders on everyday life.
This is a research project being conducted by Muscular Dystrophy Canada. The purpose of this study is to better understand the impact of neuromuscular disorders on individuals and their caregivers in Canada, which can help to inform future programs, services and policies.
If you live in Canada and:
– Are 17 years and older and live with a neuromuscular condition OR
– A parent of a child (age 2–16 years) with a neuromuscular condition OR
– A family member/caregiver to someone living with a neuromuscular disorder (age 0+)
The survey should take approximately one hour to complete. If necessary, you can save and return to the survey at any time.
You can complete the questionnaire online at oursurvey.ca/MDC
You can also email or call 1 800 567-2873 ext. 9037 to schedule a time to complete the questionnaire by phone.
Si vous avez une maladie neuromusculaire ou si vous vous occupez d’une personne qui en est atteinte, nous avons besoin de vous! Nous vous invitons à répondre à un questionnaire sur les coûts qu’implique le fait de vivre avec une maladie neuromusculaire et l’impact de ces maladies sur la vie quotidienne.
Ce projet de recherche est une initiative de Dystrophie musculaire Canada et vise à mieux comprendre l’impact des maladies neuromusculaires sur les personnes et leurs proches aidants au Canada. Cette étude nous aidera à effectuer des changements positifs et guidera nos futurs programmes, services et politiques.
Si vous vivez au Canada et :
– Que vous avez 17 ans ou plus et avez une maladie neuromusculaire OU
– Que vous êtes parent d’un enfant de 2 à 16 ans atteint d’une maladie neuromusculaire OU
– Que vous êtes un proche ou une proche aidante d’une personne atteinte d’une maladie neuromusculaire
Répondre à ce questionnaire devrait vous prendre environ une heure. Au besoin, vous pouvez en tout temps sauvegarder vos réponses et compléter le sondage plus tard.
Vous pouvez répondre à notre questionnaire en ligne oursurvey.ca/MDC
Vous pouvez aussi répondre à ce sondage par téléphone en prenant d’abord rendez-vous, soit par courriel à , soit par téléphone au 1 800 567-2873, poste 9037.
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.